profit from every $100 of sales.
$0$100
Apogee Therapeutics
We have no price for Apogee Therapeutics since 2 September 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$135.07-0.01% today
+240.0% in 1 year
1-year low $39.731-year high $135.08
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Apogee Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$256 million of profit last year.
SalesProfit
Apogee Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Apogee Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Apogee Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -31 | -93 | -217 | -286 | |
| -31 | -93 | -217 | -284 | |
| -40 | -84 | -182 | -256 | |
| -1.46 | -3.36 | -3.30 | -3.74 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 152 | 401 | 754 | 937 |
| Cash | 152 | 118 | 142 | 132 |
| Total debt | 0 | 2 | 12 | 9 |
| Total liabilities | 10 | 21 | 37 | 33 |
| 0 | 380 | 717 | 904 | |
| 27 | 25 | 55 | 68 | |
| – | -19.2% | -23.5% | -24.7% | |
| – | -22.1% | -25.4% | -28.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -16 | -75 | -171 | -227 | |
| – | 0 | 1 | 5 | |
| -16 | -75 | -172 | -233 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 6 | 23 | 46 |
Valuation
- –
- –
- –
- 11.3×
- –
- –
- –
- -2.3%
- -2.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -25.3%
- -23.1%
- -32.6%
- -21.2%
- -24.2%
- –
Growth
- –
- –
- −35.0%
- –
- +35.9%
Financial health
- -0.4×
- 0.01
- 0.6%
- –
- 26.57
- 32.59
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 952
Bottom 21%of 877
Bottom 29%of 988
What analysts expect
- Average price target
- $109.44
- Range
- $83.00 – $140.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -1.06 | -1.12 | +5.4% |
| Mar 2, 2026 | -1.03 | -1.05 | +1.9% |
| Nov 10, 2025 | -1.11 | -1.12 | +0.9% |
| Aug 11, 2025 | -1.13 | -1.03 | −9.7% |
| May 12, 2025 | -0.95 | -1.19 | +20.2% |
| Mar 3, 2025 | -1.19 | -0.94 | −26.6% |
| Nov 12, 2024 | -0.86 | -0.88 | +2.2% |
| Aug 12, 2024 | -0.60 | -0.64 | +6.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
40No pass
Philip Fisher
34No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
28No pass
Questions about Apogee Therapeutics
Is Apogee Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Apogee Therapeutics AI analysis
What does Apogee Therapeutics do?
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. It is in Biotechnology, based in Waltham, MA, United States, with 261 employees.
Does Apogee Therapeutics pay a dividend?
No. Apogee Therapeutics does not pay a dividend at the moment.
Is Apogee Therapeutics stock halal?
Yes. Apogee Therapeutics passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Apogee Therapeutics stock done over the past year?
Up 240.0% over the past twelve months, to $135.07. It traded between $39.73 and $135.08, close to its high.
Who are Apogee Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Apogee Therapeutics's.
Prices: daily closes to Sep 2, 2026. Fundamentals: company reports via invest-like data.